<SEC-DOCUMENT>0001144204-13-001091.txt : 20130107
<SEC-HEADER>0001144204-13-001091.hdr.sgml : 20130107
<ACCEPTANCE-DATETIME>20130107164537
ACCESSION NUMBER:		0001144204-13-001091
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130107
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130107
DATE AS OF CHANGE:		20130107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDIFAST INC
		CENTRAL INDEX KEY:			0000910329
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS [2090]
		IRS NUMBER:				133714405
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31573
		FILM NUMBER:		13515689

	BUSINESS ADDRESS:	
		STREET 1:		11445 CRONHILL DRIVE
		CITY:			OWINGS MILLS
		STATE:			MD
		ZIP:			21117
		BUSINESS PHONE:		7327640619

	MAIL ADDRESS:	
		STREET 1:		11445 CRONHILL DRIVE
		CITY:			OWINGS MILLS
		STATE:			MD
		ZIP:			21117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHRITE INC
		DATE OF NAME CHANGE:	19951120

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XX
		DATE OF NAME CHANGE:	19950619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	00
		DATE OF NAME CHANGE:	19950619
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v331552_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported) January 7, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MEDIFAST, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; font-weight: bold; text-align: center"><U>Delaware</U></TD>
    <TD STYLE="width: 34%; font-weight: bold; text-align: center"><U>000-23016</U></TD>
    <TD STYLE="width: 33%; font-weight: bold; text-align: center"><U>13-3714405</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">(State or other jurisdiction</TD>
    <TD STYLE="font-weight: bold; text-align: center">(Commission File Number)</TD>
    <TD STYLE="font-weight: bold; text-align: center">(IRS Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">of incorporation or organization)</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Ident. No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 67%; font-weight: bold; text-align: center"><U>11445 Cronhill Drive, Owing Mills, Maryland</U></TD>
    <TD STYLE="width: 33%; font-weight: bold; text-align: center"><B><U>21117</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="font-weight: bold; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Registrant's telephone number, including
area code <U>(410)-581-8042</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Item 5.02 Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) On January 7, 2013, Medifast, Inc. (the &ldquo;Company&rdquo;)
announced the appointment of Timothy G. Robinson, 50, as the Company&rsquo;s Chief Financial Officer, commencing on February 1,
2013. Prior to joining the Company, Mr. Robinson was Vice President, Business Operations for Canon Business Solutions, Inc. from
2008 &ndash; 2013, where he served as a key member of the executive team for this national office products subsidiary of Canon
U.S.A. From 1995 to 2008, Mr. Robinson was Vice President, Finance &amp; Administration for Canon Business Solutions-East, Inc.
Mr. Robinson was Controller of Dupli-Fax, Inc. from 1989 to 1995 and was a Senior Emerging Business Consultant for Deloitte &amp;
Touche from 1985 to 1989. Mr. Robinson received his Bachelor of Science degree in accounting from Villanova University and is a
Certified Public Accountant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The material terms of Mr. Robinson&rsquo;s employment with the
Company are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Mr. Robinson will be paid an annual base salary of $300,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Mr. Robinson will be eligible to participate in the Company&rsquo;s executive bonus plan which includes a target cash bonus
potential of 60% of base salary and a maximum cash bonus of 120% of base salary and a target share award potential of 5,000 restricted
shares and a maximum share award potential of 10,000 restricted shares, each based on the Company&rsquo;s 2013 performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Mr. Robinson will be eligible to receive a grant of 4,000 restricted shares each year over the next 3 years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>To the extent that Mr. Robinson is not paid a 2012 bonus by his former employer, the Company will provide Mr. Robinson with
a one-time sign on bonus in the amount of $30,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>If Mr. Robinson&rsquo;s employment is terminated by the Company without cause, Mr. Robinson will be eligible to receive severance
equal to twelve months of his base salary and bonus payable for the year in which his employment is terminated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Mr. Robinson will be eligible for the Company&rsquo;s standard executive relocation benefits and will be eligible to participate
in the standard benefit programs offered by the Company to its executives.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 7.01</B></TD><TD STYLE="text-align: justify"><B>Regulation FD Disclosure</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 7, 2013
the Company issued a press release announcing the appointment of Mr. Robinson as set forth in Item 5.02 of this Current Report
on Form 8-K. A copy of the press release is furnished with this Form 8-K as Exhibit 991. Exhibit 99.1 shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise
subject to the liabilities of that Section, and shall not be incorporated by reference into any filing under the Securities Act
of 1933, as amended, or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><U>Exhibit No</U>.</TD><TD STYLE="text-align: justify"><U>Description</U></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">99.1</TD><TD STYLE="text-align: justify">Press release issued by the Company on January 7, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 50%; text-indent: 0in">MEDIFAST, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Dated: January 7, 2013</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">/s/ Jason L. Groves</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Executive Vice President, General Counsel</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v331552_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Medifast, Inc. Announces Appointment
of New Chief Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OWINGS MILLS, Md., January 7, 2013 &ndash; Medifast, Inc. (NYSE:
MED), a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs,
today announced the appointment of Timothy G. Robinson as Chief Financial Officer, effective February 1, 2013. Mr. Robinson will
replace Joseph Kelleman who has been serving as the Company's Chief Financial Officer on an interim basis since December 2012.
Mr. Kelleman will continue in his role as Director of Finance &ndash; Supply Chain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Robinson brings over 25 years of diverse management experience
in finance, accounting, and business operations. Most recently, he held the position of Vice President, Business Operations for
Canon Business Solutions, Inc. from 2008 &ndash; 2013, where he served as a key member of the executive team for this national
office products subsidiary of Canon U.S.A. While in this role, Mr. Robinson led a 450 person organization, managed several business
acquisitions that strengthened the Company&rsquo;s U.S. presence, and was an executive member of the integration team that formed
the over $1 billion Canon Solutions America, Inc. business. From 1995 to 2008, Mr. Robinson was Vice President, Finance &amp; Administration
for Canon Business Solutions-East, Inc. where he directed all financial and administrative functions including accounting, budgeting,
financial reporting and analysis, credit and collections, IT, logistics, customer service, contracts administration, general affairs
and real estate operations for the Eastern regions of the U.S.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;We are excited to have Tim join Medifast
given his significant financial and accounting experience and believe his ability to develop and implement new financial processes
and systems will create the financial platform needed to support our future growth initiatives,&quot; commented Mr. Michael C.
MacDonald, Medifast&rsquo;s Chairman and Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;I am extremely excited to join Medifast
given its industry leading position and strong long-term growth potential,&quot; stated Mr. Robinson. &quot;I look forward to working
with the Medifast team to drive future growth and profitability and further position the Company as a leading manufacturer and
provider of weight-loss products and programs.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Robinson was Controller of Dupli-Fax,
Inc. from 1989 to 1995 and was a Senior Emerging Business Consultant for Deloitte &amp; Touche from 1985 to 1989. Mr. Robinson
received his Bachelor of Science degree in accounting from Villanova University and is a Certified Public Accountant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Medifast</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Medifast (NYSE: MED) is the leading easy-to-use, clinically
proven, portion-controlled weight-loss program. The company sells its products and programs via four unique distribution channels:
1) the web and national call centers, 2) the Take Shape For Life personal coaching division, 3) Medifast Weight Control Centers,
and 4) a national network of physicians. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information,
log onto www.MedifastNow.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please Note: This release contains &quot;forward-looking statements&quot;
within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934,
as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified
by use of phrases or terminology such as &quot;intend&quot; or other similar words or the negative of such terminology. Similarly,
descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking
statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities
and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties,
and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent Health Coaches
and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers,
increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and
new channels of distribution. Although Medifast believes that the expectations, statements, and assumptions reflected in these
forward- looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary
statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual
Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission,
including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of
this release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: #000033; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact: </B><BR>
Katie Turner (646) 277-1228 <FONT STYLE="color: Blue"><U>Katie.turner@icrinc.com</U></FONT></P>

<P STYLE="color: #000033; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: #000033; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B><BR>
Alecia Pulman (203) 682-8224 <FONT STYLE="color: Blue"><U>apulman@icrinc.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``Z`0$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T'7?%7B?P
MY^\U*W\/06S.5CGDN9U5O3.(R%/L36&?BU=#_E]\*#W%[.?_`&E7K$D:2H4D
M170]589!K@_$?@B^=Y[[2]8N$CQN^Q"QMYSGN$+@?D35)QZB.:E^+%X[X76]
M`C(Y*P65U.,>[?+@?05S/Q'\2W7B2QTJX-S$J1;E>&WF)BE8\B5"<$C@@AL,
MAZCD$Q:Q;RR01Q:]XC?2;68;XK6?3P)Y`"1O>.$`(N0<!F)XS7/WFA-#IK7.
MEZQ::I8?:(XW\C<C)(V0FZ-P",X(!&16J2W$V>GVWQ$OM&T/3;%K[2_,AMU6
M2[U!Y7:X(')1(P6V#IO;&[&0".:MP_%:Z91EO#,W^TNJM%G\'CR*\H.FQ6=^
M\M[XJL;?4HY#N$:RSL''!RRJ5..AP2.U=EH6CZMKEU%;1OIXD>,2K<IH,$UN
MZ$D!Q+A<="-I`8$$8I.*"YU8^*EP2`+?P\2>@&O)D_\`CE=IH-_KE^))-5TN
MUL8MH,7E7?G,^>Y^48%5?#OA"VT:W5KO[)>WH8-YRV,4(0_[`5>/Q)-8VH_%
MSP_I.H3V%]:ZI#<P-MDC:W'!_P"^N01R#6;UTBAG>T5@^%O%VE>+[.:YTMI=
ML$GER),FUE.,CCTK>J6K#"BN/\2?$KP_X6U7^S;\W3W(C$C""+<%!Z9.1SQ3
M-`^)FC>)=473]+M-2EF(W,3``L:_WF.[@4^5VN%SLZ***D`HHHH`****`"BB
ML'5_&OAO0KY;+4]7M[>Y(!\MLDJ#T+8!V_CBFE<#>HIL<B2QK)&ZNC@,K*<@
M@]"#3J0!1110`4444`%%%%`!1110`4444`%%%%`!1110!POCGPIY]Q_PE5CJ
M_P#96H6-LPDF>(2QR1#)(93^/K]*\KO[OQ7J7A*&]N-'TVVTZXO8'2YBMU@D
MGDW80D`\C)ZX^E?0][9P:A8SV=U&)()XVCD0]U(P17SWJUOKEI!J&BZ=J;W&
M@:5JL%K$MX%+I,6&T#`SM#'V!';M6L'<3-@1^*]1\5?\(UJO]G>')-11W,MG
M8(3<CJP#@G)(SW%>PZ!HEKX=T.UTFRW>1;)M4N<LQ)R2?<DDUY]X`TZ\U?Q?
MJFI^)KV6[US1I?LR1C;Y$0=?O)CN1GL,?7IZG4S?0$%?-'Q8G6?XD:EM(Q&L
M49^H0'^M?2]>$>#;&+Q;\3?%4\P#020W*9(S@.VQ?_'0:=/2[!D?P/U7[-XF
MOM,=L)>6^]!ZO&?_`(EC^5>\331V\$D\SA(HU+NQZ``9)KY2\-W\GAGQG874
MQ*M9W?ES_P"[DH_Z$U[;\8O$']D^#&LHGQ/J3>2,=?+'+G\L#_@5.<;R$GH>
M%>(]:?Q#XCO]5?(^TRED4_PH.%'_`'R!7JGP%A3RM=GP/,WPIGVPQ_K6!XQ\
M,CP[\+?#J21A;N6Z,UP<<AGC)V_@`!^%;WP%D^37HN^Z!OT<5<G>&@+<]EHK
MR?XF_$VZT2^;0M#94NT4&YNB`WEY&0J@\;L<DGID?A!X3^']SXJ\.1:UX@\0
M:PUS>*9(5CNB!&O\).<Y)ZXX&*RY-+L=SU^BOG&'Q?XE^'GBJZTV;49=0M;2
M;RY(+ARRR)U!4G)4X(/7&?6O5_%?Q'L-!\*V6K606ZFU%`UE$3@$$`EFQT`R
M,^_%#@T%SMZ\L^,U_JFCVFEWNF:K>V9DD:&1()2JL,;@>._!_.N,\/W_`(U^
M(_B!K7^WKJUMT'F7#P,8TB3.``JXR3VR?7TJW\5?"L?AS2=*=-6U6^:29D;[
M;<F11\N<J,<&JC&TM0OH=/\`!35=1U6RUI]1O[F[9)HPIGE+[05/3/2JOB_X
M/ZAKOBFZU2PU.VCANW#R+<*Q:,X`.,=1Q[4GP%_Y!^N?]=XO_037*>/_`!)X
MDT7QIJFG6OB'45MHW#1J)<;0RAL<>F<4[/G=A=#WS1=,31=$LM,CD:5+6%80
M[]6VC&:XOXH^/)_"=G;V6F%/[3NP6#L-PAC'&['<D\#/H?2NJ\,RS7?@_299
M9Y&GEL8F:5CN8L4&6.>ISSS7SE\0R8_'.JQM?7-[Y+A#-<$%LA02.```"2``
M!4PC>6HV]#T7X=^%I/%^F2:_XIOK[4!+(R6\$ERZH`O!8A2.^0!T&*[WPUX/
MM?#%]J,MI<W+P73*8H)9F=8%`Y"Y)ZDD_D*QO!?@IM-T31YVUO6%*Q).]FMP
M!!N8;BNW;G&3TS5H:7XKUK5[][S6I=*TA)V2U@LXD$TB#C<SL#M!.<8YQZ42
M=V]01V5%>3?$#P?>Z-X?N-<TSQ/KGF6N&ECN+UF#J2!P1C!&<U2^$7C?6-2U
MN71-5O)+R-H&EADE.70J1D;NI!![^E+DTN@N>S45XS\3OB5J>GZU-H.B3?91
M``+BY4`N6(SM7/0`$<]<UK^`M)TK7]!M[VX\1ZI?:I(F;A?[3E1H7[J$5AC'
MJ>O6CDLKL+GI]<3\1_&]QX+TZT>TM(I[B[=D0RL0L>!G)`Z]?45KZ-HVJZ3J
MT_F:U<7^E21#RHKO#2PR9_O@`LI'KR/>O)?C;826NMZ=<R7]S<"XCDVQ2E=D
M(!7A``,9SSG)XZT02<K`]COOA1K6HZ_X7N[_`%2Y:XN'OI!N/`4;4PJ@<`#T
MKNZ\7^%'A?\`M?PK<78US6;`F[>,QV-R(T.%7DC!YYZ^PKV6*/R84CW.^Q0N
MYSECCN3W-$TK@A]%%%0,****`"O`?BQ:06GCB::=9;1+F*!XVM0/W^&Q([\_
M>48V\<X%>_5XU\:(C;:MIE\KRVXEC$;31C>7*2JP!7MMR6![GBKI_$)G5_"6
MR%MX)280*@N;B65)C_K)X]V%>3D_-CM7=5SO@2T-EX(TF)HO+=H!(PW[MS.2
MQ;/OG..V<5T53+<:,_7=172-`U#4'8*+:W>3)]0IQ^M>8_`>R(T[6=1<9>69
M(0W^ZNX_J]6OBQKE]J&E'P_HVFZC<^:X-W-':2%`JG.P''))`SCC`]Z/A#>M
MI&AS:1J6GW]G<M=&2-I;20)(&"C[VW`(([U:5H"ZGFWQ/TK^S/B!JD8&([DB
MY3_@8Y_\>#5JZ#<7GQ)\<:!;WT0^S:9;)YP!)#+'R6/N[;1BNG^-GAV[OKK2
M-1L+.>YE.ZUD6&,N?[R=/^!5TWPP\%/X3T5Y[Y`-4O<-,!SY2C[J9_$D^Y]J
MOF7+<5M3-^.*`^#+-^ZWZ?JCUS/P(GVZWK,&?OVT;X^C$?\`LU;?QBN[G5M/
MM=%TS3K^[DCN/.G>*UD9$VJ0!NQ@D[NWI7(?#0:KX7\7I=7^C:I'9SPM!*XL
MI#LR002`,XR/UI+X+!U.:\<I*GCS7EF!W_;9#SZ$Y7],5[+X0\+R:SX/TFXN
M?%&L/;/:H$MK:5;=$`&-F4&XXQC)/:H/B#\.U\8K'KNB2*FH&,*\<H*+.HZ=
M1E6'3D<CZ5SO@S5_&/@.-]*U'PMJ5YIY<L@AC+-$QZ[2,@@]<9ZT-\T=`ZGI
M=E\/_"UC+YR:-;S3'DRW.9W8^I+D\UY%\:P8_%]C;I&L=O%8+Y2*,*,NV<#\
M!7H,_C+Q/K,D-GH?A/4K+SG57OM0C"+"I/S,%SR0/_U&G_$OP%)XNL+>YL'1
M=3LP0@D.!,AZJ3V.1D'Z^M3%V>HV8OP(2(:%J\BX\YKM5?UVA!C^;4SX\?\`
M('T;_KZ?_P!`KG/`\?C'P'K4YE\+ZE<V5P`EQ%#'N.1T=2,@D9/U!K3^)MUK
M'C&'3[;3?"NN)';.TCO/:%221@``9]^:JWOW%T+GP%_Y!^N?]=XO_037"?%;
M_DI&K_\`;+_T4M>A?!C3M3T;^U[34]*O;-IC'+&\\#*K``@C)[\BN-^('A_7
M]:\<ZK?66@:G);.ZHD@MFPX5`N1QTR#33]]AT/;O"3K'X(T5V.%73X22>PV"
MOF=!)XF\9`'E]2U#]'D_P->[3ZG-I7P4:>>VFM;J#3!;-%.A1EDVB,<'W.17
ME7PCTEM1\?6DNPF&P1KASV!QM7]3^E*&EV#/I`F."$DE4CC7)).`H%>0ZQ\7
M=0U76H]&\'6<3O-*(8KJX&=Y/=5[+WR>W:O4-?T^75?#NHZ?#)Y<MS;21(YZ
M`LI`S[5\TZ?IWB;PEXGM+D:)>?;;27<L?D,ZOU!`*C!!!/(J8),;/3?B!H6H
M:=\/KR\UCQ+J%_>L8U,:LL5N6+C($:CD=>I[9KC/@W_R4.+_`*]9O_9:[+Q/
MI_B_X@>&9IKC2SI%O:+Y\%@6\R:[D'KTV@#.!C))KG/AAH6N:+XZM;K4-#U&
M"W>*2$RO;L%0L."3C@<8_&K7PL74ZKQ_\*)_$&K2ZSHUU%'<S`>=;SY"NP&-
MRL,X.`."*\LU7P)XJ\/AKFZTFX2.(;C<6[!PH]<J<C\<5[E_PD^M:+K^I6^L
M:)?S:29MUG?6D/G;4('RNJY;`.<'%1ZK\4-&M[5UTZUU#4;QE(CMX[*5<MVW
M%E&!4QE):`TCR?P7\1]?TG6K*WNK^:^T^:5(I(KAMY4,<95CR",YQG%=+\>?
M^/[0O^N<W\TJG\/?ACJMSK=MK&N6ILK.WD$R02##RN#E?E_A4'GGGC%=/\9?
M"^I:W8Z=?Z9;/=-9EUEBC&7VMCY@.^"O0>M4VN=6#H3_``0_Y$:X_P"O^3_T
M%*]*KP3X;^*-:\+076EMX8U2^BFD\U%A@961\`$'(Q@X'TKT^^\67VE:3ITU
M]I.V_O,LUL)>(1D<%L')&Y<X&.IX`J)Q=QHZRBN!_P"%KZ3_`,^-Y_XY_C14
M\K"YWU%%%2,*\X^+VCZCJ&DZ=<Z3:S3W<-TL9$6"0K$$9'^^J<]N_%>CT4T[
M.X%73;./3M+M+*)2L=O"D2@G)```Z]ZM444@"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@#S3XNS7>I6>F^%M*A:XO[^;S6B3M&G=O1=Q')]#71>!/!EO
MX-T3[.&66^G(>ZG`X9NRC_9';\3WK6TZ&+^TM3N/+3SC,(S)M&XJ$4A<]<`D
M\>YK3JF]+""BBBI&%%%%`!1110`4444`%5[NPM+^-8[RVAN$4Y"RH&`/XU8H
3H`A^QVO_`#[0_P#?`HJ:B@#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
